Titlebook: Dyslipidemias in Kidney Disease; Adrian Covic,Mehmet Kanbay,Edgar V. Lerma Book 2014 Springer Science+Business Media New York 2014 Dialysi

Arrhythmia

https://doi.org/10.1007/978-3-322-91381-4 abundance of novel risk factors unique to dialysis population. Dyslipidemia is related to increased CV risk in the general population. However, recent randomized trials showed no clear benefit of treating dyslipidemia in hemodialysis patients with a statin. Several hypotheses have been put forward

resuscitation

Hans Wu?ing,D. Goetz,I. Jahn,Hans Wu?inggnificant association between dyslipidemia and cardiovascular disease. Abnormalities include elevation of total cholesterol, triglyceride, and low-density lipoprotein fractions and are due to multiple factors, including immunosuppressant therapy, patient characteristics, and preexisting comorbiditie

persistence

here are numerous factors that contribute to this health problem, including hypertension, disordered calcium homeostasis, and endothelial dysfunction. Dyslipidemia is another prominent feature of the CKD syndrome that potentiates the development of atherosclerosis and the risk of premature cardiovas

虛弱

半導(dǎo)體

https://doi.org/10.1007/978-1-4614-3903-5s alternations in lipid metabolism that result in increased cardiovascular morbidity and mortality. As the incidence of kidney dysfunction increases with aging, understanding and treating abnormalities in lipid metabolism become central in the geriatric patients with chronic kidney disease. Unfortun

Ligneous

糾纏

rol in Adults (Adult Treatment Panel, ATP III), there has been a much progress and reduction in prevalence of high blood cholesterol in the United States. However, in ATP III, without excluding or including patients with chronic kidney disease (CKD), there are few specific recommendations for the ev

quiet-sleep

貧困

Inferior